Study | Year | Country | Study design | Number (Male) | Tumor stage | Cut-off for high CONUT group | Prevalence of high CONUT score | End points | Qualitya |
---|---|---|---|---|---|---|---|---|---|
Takagi et al. [11] | 2017 | Japan | Retrospective Single center | 295 (241) | I: 36 II: 126 III: 92 IV: 41 | ≥3 | 40.0% | OS RFS | 7 |
Harimoto et al. [12] | 2017 | Japan | Retrospective Single center | 357 (270) | I: 58 II: 187 III: 93 IV: 19 | ≥4 | 19.3% | OS RFS | 6 |
Takagi et al. [13] | 2018 | Japan | Retrospective Single center | 331 (269) | I + II: 185 III + IV: 146 | ≥5 | 9.1% | Complications | 6 |
Harimoto et al. [14] | 2018 | Japan | Retrospective Multi-center | 2461 (1785) | I + II: 1437 III + IV: 1024 | ≥4 | 21.9% | OS RFS | 6 |
Li et al. [15] | 2018 | China | Retrospective Single center | 1334 (1136) | n.a. | ≥8b | 49.4% | Complications | 8 |
Wang et al. [16] | 2018 | China | Retrospective Single center | 209 (172) | BCLC stage A: 126 B: 40 C: 43 | ≥3 | 34.5% | OS RFS PHR | 6 |
Lin et al. [17] | 2019 | China | Retrospective Single center | 380 (333) | I + II: 304 III + IV: 76 | ≥2 | 49.2% | OS RFS | 8 |